1 min read
Selexis SA to Address Recombinant Protein Expression Bottlenecks at PEPTALK 2014
Selexis CSO to Present Data on the Recently Launched SURE CHO-Mplus™ Libraries
Geneva, Switzerland December 17, 2013 –...
Selexis CSO to Present Data on the Recently Launched SURE CHO-Mplus™ Libraries
Geneva, Switzerland December 17, 2013 –...
Strategic Alliance to Provide Seamless Services from Cell Line Development to cGMP Manufacturing of Biologic Drugs
...
Former Quintile executive brings more than 15 years of life science and regulatory knowledge to Selexis
Geneva,...
Dr. Igor Fisch to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein...
CSO to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein Production...
Selexis to Meet with Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for...
Geneva, Switzerland (PRWEB) May 20, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead...
Funding to Expand the SUREtechnology Platform™
Geneva, Switzerland (PRNEWSWIRE) April 30, 2013 – Selexis SA, a serial...
Company to Present Data on recently launched Selexis SURE CHO-Mplus™ Libraries
Geneva, Switzerland (PRWEB) April 23,...
Selexis to Meet with Companies Interested in Cell Line Development and Lead Identification for Therapeutic Drug...
Dr. Armelle Gaussin to Present in the Cell Therapy/Regenerative Medicine Track
Geneva, Switzerland (PRWEB) March 8,...
New Paper Highlights Innovations in the SUREtechnology Platform™ for the Improvement of Protein Secretion of...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.